盈康生命科技股份有限公司 盈康生命科技股份有限公司 防范控股股东及关联方资金占用管理办法 （2025 年 6 月） 第一章 总则 第一条 为了建立防止控股股东及关联方占用盈康生命科技股份有限公司及 其控股子公司（以下简称"公司"）资金的长效机制，杜绝控股股东及关联方资金 占用行为的发生，根据《公司法》《上市公司治理准则》《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》《关于进一步做好清理大股东 占用上市公司资金工作的通知》（证监发[2006]128 号）、《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》以及相关法 律法规特制定本办法。 第二条 资金占用包括经营性资金占用和非经营性资金占用。经营性资金占 用是指控股股东及关联方通过采购、销售、租赁和运输服务等生产经营相关环节 的关联交易产生的资金占用；非经营性资金占用是指为控股股东及关联方垫付的 工资、福利、保险、广告等费用和其他支出，代控股股东及关联方偿还债务而支 付资金，有偿或无偿、直接或间接拆借给控股股东及关联方资金，其他在没有商 品和劳务提供情况下给控股股东及关联方使用的资金。 第二章 防范控 ...

盈康生命科技股份有限公司 盈康生命科技股份有限公司 董事、高级管理人员薪酬管理制度 （2025 年 6 月） 第一章 总则 第一条 为进一步完善公司董事与高级管理人员的薪酬管理，建立科学有效 的激励与约束机制，有效调动公司董事及高级管理人员的工作积极性，提高公司 的经营管理效益，根据《中华人民共和国公司法》《中华人民共和国证券法》等 有关法律、法规及《盈康生命科技股份有限公司章程》，特制定本薪酬管理制度。 第二条 适用本制度的董事与高级管理人员包括：公司董事、经理、副经理、 董事会秘书、财务总监。 第三条 公司薪酬制度遵循以下原则： （一）体现收入水平符合公司规模与业绩的原则，同时与外部薪酬水平相 符； （二）体现责任权利对等的原则，薪酬与岗位价值高低、承担责任大小相 符； （三）体现公司长远利益的原则，与公司持续健康发展的目标相符； （四）体现激励与约束并重、奖罚对等的原则，薪酬发放与考核挂钩、与 奖惩挂钩。 第二章 薪酬管理机构 第四条 公司董事会薪酬与考核委员会在董事会的授权下，负责公司董事、 高级管理人员的薪酬标准与方案考核及管理；负责审查公司董事、高级管理人员 履行职责并对其进行年度考核；负责对公司 ...

盈康生命科技股份有限公司 盈康生命科技股份有限公司 董事、高级管理人员离职管理制度 （2025 年 6 月） 第一章 总则 第一条 为规范盈康生命科技股份有限公司（以下简称"公司"）董事、 高级管理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华 人民共和国公司法》《上市公司章程指引》和《盈康生命科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员的 辞任、任期届满、解任以及其他导致董事、高级管理人员实际离职等情形。 第二章 离职情形与生效条件 第三条 董事可以在任期届满以前辞任。董事辞任应向董事会提交书 面辞职报告，公司收到辞职报告之日辞任生效，公司将在两个交易日内披 露有关情况。 第四条 如存在以下情形的，在改选出的董事就任前，原董事仍应当 依照法律、行政法规、部门规章和《公司章程》规定，履行董事职务，但 存在相关法规另有规定的除外： （三）独立董事辞职导致董事会或者其专门委员会中独立董事所占比 例不符合法律、行政法规或者《公司章程》规定，或者独立董事中欠缺会计 1 盈康生命科技股份有限公司 专业人士。 第五条 董 ...

Group 1 - The high-pressure oxygen chamber concept increased by 1.54%, ranking 6th among concept sectors, with five stocks rising, including Aoyang Health, which hit the daily limit, and Yingkang Life, Jinling Pharmaceutical, and International Medicine showing gains of 4.30%, 1.70%, and 0.58% respectively [1][2] - The main capital inflow into the high-pressure oxygen chamber concept was 0.52 billion yuan, with Aoyang Health receiving the highest net inflow of 68.73 million yuan, followed by Yingkang Life and Samsung Medical with net inflows of 11.24 million yuan and 9.36 million yuan respectively [2][3] - Aoyang Health, Yingkang Life, and Tiedean Heavy Industry had the highest net inflow ratios of 7.40%, 3.64%, and 3.00% respectively, indicating strong investor interest [3][4] Group 2 - The top-performing stocks in the high-pressure oxygen chamber concept included Aoyang Health with a daily increase of 10.12% and a turnover rate of 26.84%, while other notable stocks included Yingkang Life and Samsung Medical with increases of 4.30% and 0.17% respectively [3][4] - Stocks that experienced declines included Innovative Medical, Tiedean Heavy Industry, and Weiao Co., with decreases of 1.56%, 0.74%, and 0.68% respectively, indicating some volatility within the sector [1][4]

Transaction Overview - The company has approved the acquisition of 51% equity in Changsha Kexin Tumor Hospital Co., Ltd. for a total amount of RMB 357 million [1] - The valuation for the equity transfer was based on an asset evaluation report from Shanghai Dongzhou Asset Appraisal Co., Ltd. [1] Progress Update - All parties involved have confirmed the completion of pre-delivery obligations as per the equity transfer agreement [2] - The company has made the initial payment for the equity transfer to Hunan Kexin Health Industry Group Co., Ltd. [2] - The equity transfer has been officially registered, and the business license for Changsha Kexin has been updated [2] Changes in Business Registration - After the completion of the business registration change, the company now holds 51% of Changsha Kexin, making it a subsidiary included in the company's consolidated financial statements [2] - The updated shareholding structure shows the company holding 51% and Kexin Group holding 49% [2]

盈康生命科技股份有限公司 关于收购长沙珂信肿瘤医院有限公司51%股权 证券代码：300143 证券简称：盈康生命 公告编号：2025-025 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、交易概述 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开第 六届董事会第十六次会议、第六届监事会第十四次会议，审议通过了《关于收购长 沙珂信肿瘤医院有限公司 51%股权的议案》，同意公司收购长沙珂信肿瘤医院有 限公司（以下简称"长沙珂信"）51%股权（以下合称"本次交易"）。本次交易 股权转让的价格以上海东洲资产评估有限公司出具的《盈康生命科技股份有限公 司拟收购长沙珂信肿瘤医院有限公司部分股权所涉及的长沙珂信肿瘤医院有限公 司股东全部权益价值资产评估报告》（东洲评报字[2025]第 0058 号）为定价参考 依据，经交易各方协商确定，本次交易总金额为人民币 35,700 万元。具体内容详 见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于收购长沙珂信肿瘤医院有 限公司 51%股权的公告》（公告编号：20 ...

Financial Performance - In Q1 2025, the company achieved a revenue of 409.037 million yuan, maintaining stability [3] - Net profit attributable to shareholders was 29.993 million yuan, a year-on-year increase of 14.4% [3] - Net profit excluding non-recurring items was 29.965 million yuan, up 25.8% year-on-year [3] Business Strategy - The company focuses on the integration of traditional medical services with AI technology to enhance operational efficiency and service quality [6] - The healthcare service revenue accounted for 76.47% of total income in 2024 [6] - The company is transitioning from a traditional medical group to a technology-driven health management provider [6] Mergers and Acquisitions - The company plans to continue acquisitions, targeting profitable hospitals with a minimum of 400 beds for general hospitals or 300 beds for specialty hospitals [4] - The acquisition of Changsha Kexin is expected to enhance business scale and profitability, particularly in oncology services [8] AI Integration - The company is implementing a comprehensive AI strategy across its operations, focusing on improving diagnostic capabilities, patient experience, and operational management [4] - AI applications are structured in three layers: data infrastructure, capability components, and intelligent interaction engines [4] Operational Efficiency - In 2024, the company achieved a revenue per employee of 710,000 yuan, an increase of 8.9% year-on-year [5] - Profit per employee reached 52,600 yuan, reflecting a year-on-year growth of 20.2% [5] Care Services Development - The company is expanding its nursing and elderly care services, leveraging its existing facilities in Shanghai [3] - Plans include enhancing home care services and integrating traditional and modern medical practices [3]

证券代码：300143 证券简称：盈康生命 公告编号：2025-024 盈康生命科技股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，盈康生命科技股份有限公司（以下简称 "公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"，现将相 关事项公告如下： 本次集体接待日活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net）；或关注微信公众号（名称:全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00—17:00。 届时公司高管将以在线交流形式就公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 盈康生命科技股份有限公司董事会 二〇二五年四月三十日 1 ...

Core Viewpoint - 盈康生命科技股份有限公司 continues to demonstrate steady growth in 2024, driven by its differentiated and AI-enabled strategies, enhancing operational efficiency and profitability [2][3]. Financial Performance - In Q1 2025, the company achieved revenue of 409 million yuan, a year-on-year decrease of 1.73%; net profit attributable to shareholders was 30 million yuan, an increase of 14.4%; and non-recurring net profit was also 30 million yuan, up 25.77% [2]. - For the full year 2024, the company reported revenue of 1.559 billion yuan, a year-on-year increase of 6.01%, and a net profit of 115 million yuan, up 14.92% [2]. - The compound annual growth rates for revenue and net profit over the past five years were 23.9% and 14.9%, respectively, indicating a trend of high-quality development [2]. AI Empowerment and Innovation - Since 2021, the company has strategically positioned itself in the "medical + AI" sector, establishing itself as a pioneer in group AI deployment within the industry [3]. - The company embraces a "three-full" concept of AI, focusing on full participation, full coverage, and full process, to enhance diagnostic capabilities, patient experience, and operational management [3]. - In 2024, the company reported an 8.9% increase in revenue per capita and a 20.2% increase in profit per capita, while the period expense ratio decreased by 0.8 percentage points [3]. Differentiated Development Path - The company has driven business growth through a differentiated approach, with the medical services segment generating revenue of 1.19 billion yuan in 2024, of which tumor-related revenue was 380 million yuan, accounting for 31.9% of medical service revenue, an increase of 17% year-on-year [4]. - The company has developed a "three-special" system focusing on specialized departments, diseases, and expertise, integrating medical innovation to enhance user experience and meet diverse needs [4]. External Growth Strategy - In 2025, the company plans to deepen its tumor medical specialty through external growth, announcing a cash acquisition of 51% of Changsha Kexin Tumor Hospital for 357 million yuan [6]. - Changsha Kexin, established in 2015, is a tertiary tumor specialty hospital with 420 beds and advanced radiotherapy equipment, performing over 8,000 minimally invasive surgeries annually [6]. - The acquisition is part of the company's strategy to enhance its regional medical center layout and is expected to significantly improve its technical depth and service breadth in the tumor specialty field, thereby strengthening its profitability [6].

Core Viewpoint - Yingkang Life reported a slight decline in revenue but a significant increase in net profit, showcasing strong profitability and growth potential in a challenging private hospital industry [1][2][4] Financial Performance - Revenue for Q1 2025 decreased by 1.73% year-on-year to 409 million yuan, while net profit attributable to shareholders increased by 14.4% to 29.993 million yuan [1] - Non-recurring net profit surged by 25.8% year-on-year to 29.965 million yuan, indicating improved profit quality [2] Operational Efficiency - The company achieved a reduction in operating expenses, with the expense ratio decreasing by 2.9 percentage points [2] - The oncology revenue share rose to 31.9%, up 17 percentage points from the previous year, becoming a key growth driver [2] Strategic Initiatives - Yingkang Life announced the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, aiming to enhance its regional medical center layout and expand oncology treatment capabilities [2] - The company has implemented an "AI + Medical" strategy since 2021, integrating AI across all aspects of diagnosis, management, and service [3] Technological Advancements - The launch of the "AI Innovation Application Platform" in April 2023, in collaboration with industry leaders, aims to enhance the entire service chain from disease screening to health management [3] - The company is transitioning from "tool empowerment" to "ecosystem reconstruction" in AI healthcare, providing a replicable model for intelligent transformation in the industry [3] Industry Positioning - Yingkang Life stands out in the private hospital sector, successfully navigating cost pressures and achieving profit growth while many smaller private hospitals face losses [3][4] - The company is positioned as a benchmark for transformation in the private hospital industry, leveraging AI, specialization, and external expansion to enhance quality alongside scale [4]